Clinical trials: Malignant Neoplasm of Prostate
Metastatic Breast Cancer, Metastatic Prostate Cancer
Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
The REaCT-CHRONO-MetBP Pilot study will compare morning and evening administration of endocrine-based therapy in metastatic breast and prostate cancers.
- Trial name
- NCT07252726
- Testing
- Morning administration of CDK4/6 inhibitor, Evening administration of CDK4/6 inhibitor, Morning administration of ARPI
- Where
- 3 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Ottawa Hospital Research Institute
Breast Cancer, Glioma
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast…
- Conditions
- Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00909558
- Testing
- Autologous Natural Killer / Natural Killer T Cell Immunotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Envita Medical Center, Inc.
Prostatic Neoplasms, Neoplasm Metastasis
Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
Primary objective was to demonstrate overall survival improvement with aflibercept compared to placebo in patients receiving docetaxel / prednisone for metastatic androgen-independent prostate cancer (MAIPC).
- Trial name
- VENICE (NCT00519285)
- Testing
- Aflibercept, Docetaxel, Prednisone or Prednisolone
- Where
- 31 sites in United States, Argentina and 29 more
- Volunteers
- 1,224 people
- Sponsor
- Sanofi
Malignant Brain Neoplasm, Malignant Solid Neoplasm
Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
This clinical trial studies the effect of respiratory training for enhancing brain and mental health among patients with multiple sclerosis (MS) and cancer (along with their caregivers).
- Conditions
- Malignant Brain Neoplasm, Malignant Solid Neoplasm, Multiple Sclerosis, Neuroendocrine Tumor
- Trial name
- NCT06788886
- Testing
- Biospecimen Collection, Exercise Intervention, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Motor Function, Cognitive Function
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Trial name
- ODYSSEY (NCT04373564)
- Testing
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain
- Where
- 51 sites in United States, Brazil and 6 more
- Volunteers
- 2,076 people
- Sponsor
- Guerbet
Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC
This is one center, single-arm, open-label investigator initiated trial to assess the safety and efficacy of enhanced autologous PSMA chimeric antigen receptor T cells in the treatment for patients with refractory castration…
- Trial name
- NCT06228404
- Testing
- Enhanced autologous PSMA-CAR T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Changzheng Hospital
Castration-resistant Prostate Cancer, Metastatic Cancer
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
- Trial name
- CANOPY (NCT05502315)
- Testing
- Cabozantinib, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 47 people
- Sponsor
- Rana McKay, MD
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Prostate Cancer
Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients
The purpose of this research study is to learn about: 1) How standard radiation treatment to prostate (primary radiotherapy) or the pelvis after prostatectomy (postoperative radiotherapy) may cause changes in MRI and PET imaging…
- Trial name
- COMBINE (NCT02997709)
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- University of Miami
Prostatic Neoplasm, Genital Neoplasms, Male
Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
To investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.
- Conditions
- Prostatic Neoplasm, Genital Neoplasms, Male, Neoplasms, Abdominal, Urogenital Neoplasms
- Trial name
- NCT01316458
- Testing
- STI571 (Glivec®)
- Where
- 13 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499291
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, gene expression analysis, laboratory biomarker analysis
- Sponsor
- Eastern Cooperative Oncology Group
Prostate Cancer, Prostatic Neoplasm
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
The purpose of this study is to show that abiraterone acetate plus prednisone added to the current standard of care, gonadotropin-releasing hormone (GnRH) decreases prostate specific antigen (PSA) and prolongs the time until it…
- Trial name
- NCT01314118
- Testing
- abiraterone acetate in combination with prednisone
- Where
- 45 sites in United States
- Volunteers
- 131 people
- Sponsor
- Janssen Biotech, Inc.
Prostate Cancer
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
The primary objective of this study is to compare the duration of survival between patients receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus patients receiving docetaxel and prednisone…
- Trial name
- NCT00133224
- Testing
- Immunotherapy allogeneic GM-CSF secreting cellular vaccine, Chemotherapy (docetaxel and prednisone)
- Where
- 115 sites in United States, Belgium and 8 more
- Volunteers
- 408 people
- Sponsor
- Cell Genesys
Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
The goal of this clinical trial is to is to investigate if it is possible to lower the chance of cancer reoccurrence and also preserve quality of life by using the drug Pluvicto instead of androgen-deprivation therapy to the…
- Trial name
- STARLiT (NCT06574880)
- Testing
- Lu-PSMA-617, 5-fraction Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Angela Y. Jia, MD PhD
Metastatic Cancer, Prostate Cancer
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin and leuprolide may fight prostate cancer by stopping the adrenal glands from producing androgens.
- Trial name
- NCT00081159
- Testing
- Doxorubicin hydrochloride, Goserelin acetate, Leuprolide acetate
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Prostatic Neoplasms
EPO906 Therapy in Patients With Prostate Cancer
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause prostate cancer.
- Trial name
- NCT00035113
- Testing
- epothilone b
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer, Solid Tumor (Not Breast or Prostate Cancers)
Cabozantinib in Advanced Solid Malignancies
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01588821
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Prostate Cancer
Tivozanib + Enzalutamide in Adv Prostate Cancer
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational combination of drugs to learn whether they work in treating a specific cancer.
- Trial name
- NCT01885949
- Testing
- Tivozanib, Enzalutamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Massachusetts General Hospital
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle.
- Conditions
- Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
- Trial name
- NCT04729114
- Testing
- PRL-02 injection, prednisone, dexamethasone
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Astellas Pharma Global Development, Inc.